Erythropoietin Products By Dolphin Pharma
Dolphin Pharmaceuticals offers a range of Erythropoietin Medicines designed to help to treat anemia. Our products are developed with a strong focus on quality, safety, and therapeutic effectiveness. We support healthcare professionals with dependable pharmaceutical solutions designed to promote consistent patient care. All medicines are manufactured in compliance with established quality standards.
Cresp (Darbepoetin alfa) 40 mcg
Generic Name: Darbepoetin alfa 40mcg
Dolphin Pharmaceuticals offers a range of Erythropoietin Medicines designed to help to treat anemia. Erythropoietin products are medicines designed to stimulate the production of red blood cells in the bone marrow. They work similarly to the natural hormone erythropoietin, which is primarily produced by the kidneys and helps maintain healthy red blood cell levels in the body. These products are commonly used to treat anemia associated with chronic kidney disease, where reduced erythropoietin production can lead to a decrease in red blood cell counts. They may help improve hemoglobin levels and relieve symptoms such as fatigue, weakness, and reduced exercise tolerance. Certain erythropoietin products are also prescribed for selected patients experiencing anemia due to cancer chemotherapy. By stimulating red blood cell formation, these medicines may reduce the need for red blood cell transfusions in eligible patients, depending on their clinical condition and treatment plan. Erythropoietin products include erythropoietin-stimulating agents such as epoetin alfa and darbepoetin alfa. These medicines differ in their formulation, duration of action, dosage schedules, and approved indications. The choice of product depends on the patient's medical history, the underlying cause of anemia, and the treating doctor's recommendations. These medicines are generally administered by injection, either intravenously or subcutaneously, depending on the specific product and clinical circumstances. Regular monitoring of hemoglobin levels, blood pressure, and iron status is important to assess treatment response and ensure appropriate dosing throughout therapy. Although erythropoietin products can provide significant benefits for eligible patients, they may increase the risk of high blood pressure, blood clots, stroke, and other cardiovascular complications. They should therefore be used under medical supervision, with individualized dosing and regular follow-up to support safe and effective anemia management.